The new injectable technology incorporates the use of discography with the administration of the company’s DiscSeal, a percutaneous injectable agent for soft tissue engineering, designed to fill and seal the disc defect and treat internal disc derangement (IDD).

SpineOvations CEO Ross Simmonds said this particular whole body patent protection provides them and their licensees with a marketing advantage over other products using similar active ingredients but it in limited applications.

"A key application of SpineOvation’s technology concept will also provide a method for alleviating pain symptoms in a potentially enormous population of patients by delivering appropriate amounts of collagen based material into ligaments and joints requiring repair," Simmonds said.